Dr. Christian Werner is currently the Executive Director of Global Medical Affairs and the Global Duchenne Muscular Dystrophy (DMD) and Gene Therapy Lead at PTC Therapeutics, Germany, since February 2024. He is responsible for developing and implementing global medical strategies, with a focus on Duchenne Muscular Dystrophy and gene therapy.

Dr. Werner's career in the pharmaceutical industry began after years of clinical and academic experience. He completed his medical degree (Dr. med.) at Heinrich-Heine University in Düsseldorf in 2001, with a thesis focused on hereditary affective psychosis. He earned his full medical license in 1999 and received his Certificate of Completion of Specialist Training (Facharzt) in Psychiatry and Psychotherapy in 2003.

From January 2021 to February 2024, Dr. Werner served as Executive Director of Global Medical Affairs and Global DMD Lead at PTC Therapeutics. Prior to that, between October 2019 and December 2020, he was Executive Director of Medical Affairs for Northern Europe, leading a multidisciplinary team of Medical Directors and Medical Science Liaisons (MSLs). His work centered on rare diseases, including AADC deficiency and Duchenne Muscular Dystrophy.

Earlier roles at PTC Therapeutics included Executive Director of Medical Affairs for Europe (2017-2019) and Senior Director for the D-A-CH region (Germany, Austria, Switzerland) from 2017.

Before joining PTC, Dr. Werner held senior positions at Otsuka Pharma GmbH, serving as Senior Medical Director and Medical Director from 2005 to 2016. His focus areas spanned psychiatry, nephrology, endocrinology, and oncology.

In addition to his medical education, Dr. Werner completed specialized training in health economics at the European Business School and holds certifications in pharmacovigilance, drug safety, and market access. His career reflects a blend of clinical expertise and leadership in the development of treatments for rare diseases.